Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Lyell Immunopharma, Inc.

LYEL ✗ NOT COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$11.96

▼ -1.97%

Market Cap $293.08M · Vol 61.72K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$293.08M

Micro Cap

Div Yield

N/A

EPS Growth

+53.36%

YoY

RSI (14)

22.28

Momentum

Beta

-0.04

vs Market

52W High

$44.47

73.11% below

52W Low

$11.54

3.68% above

Volume

61.72K

Avg 55.85K

P/B

2.64

Price-to-book

ROE

-86.98%

Return on equity

Free Float

59.32%

Public shares

Shariah Compliance8 STANDARDS

✗ Lyell Immunopharma, Inc. (LYEL) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does LYEL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-16.48%

-19.62%

-12.83%

-52.43%

YTD

-61.14%

-10.08%

-68.53%

-96.67%

Financials & Valuation

TTM · Annual

Total Revenue	$36.00K
Net Income	$-274,448,000.00
Revenue Growth (YoY)	-50.00%
Gross Margin	100.00%
Operating Margin	-560,080.56%
Net Profit Margin	-762,355.56%
ROE	-86.98%
ROA · ROIC	-66.06% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	14,614.52
P/B	2.64
P/FCF	N/A
EPS Growth	+53.36%
Outstanding Shares	24.51M

Technical Indicators

50-Day SMA	$14.04
200-Day SMA	$20.19
RSI (14)	22.28
Beta	-0.04
52-Week High	$44.47
52-Week Low	$11.54

Volume Today	61.72K
Avg Daily Volume (30D)	55.85K
Relative Volume	1.11x
Volatility (10D)	46.30
Volatility (30D)	71.29
Free Float	59.32%

Analyst Consensus

BUY

Current Price $11.96

Mean Target $37.88

52W Low$11.54 52W High$44.47

Current

Target

$11.54 $44.47

Current Analyst target

+216.72% upside potential · 9 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00RNXFN23

ISINUS55083R2031

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -1.15% ARGX.BR argenx SE -0.23% ARGX argenx SE +0.04% INSM Insmed Incorporated +1.67% 2269.HK WuXi Biologics (Cayman) Inc. -1.05%

Company Profile

Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.